PTC Therapeutics Q2 revenue $361 million
PTC Therapeutics reported Q2 2026 revenue of $361 million, raised full-year product revenue guidance, and announced strong Sephience revenue, a $50 million Novartis milestone, and new pipeline developments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day